Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001013594-25-000650
Filing Date
2025-05-14
Accepted
2025-05-14 17:49:52
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11985
2 JOINT FILING AGREEMENT ex99.htm EX-99.1 5501
  Complete submission text file 0001013594-25-000650.txt   19148
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91484 | Film No.: 25947417
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 150 EAST 58TH STREET 14TH FLOOR NEW YORK NY 10155
Business Address 150 EAST 58TH STREET 14TH FLOOR NEW YORK NY 10155 212-702-8644
Madison Avenue Partners, LP (Filed by) CIK: 0001801265 (see all company filings)

EIN.: 320567414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G